Apr 11, 2022
Eric Adams is the CEO and President of InMed Pharmaceuticals, exploring the benefits of rare cannabinoids from the cannabis plant. We have these naturally occurring cannabinoids in our body and a number of receptors throughout our body that respond to this class of compounds. Because these rare cannabinoids exist in low quantities in the plant, they have been hard to isolate or extract, which has limited research into their therapeutic value. InMed has developed ways to economically manufacture bioidentical compounds and investigate potential benefits for treating eye and skin disorders.
Eric elaborates, "InMed Pharmaceuticals is a global leader in the manufacturing, clinical development, and commercialization of non-intoxicating, rare cannabinoids. We have two branches to the company. One is the pharmaceutical drug development program where we're taking the traditional clinical trial, FDA pathway approach to bringing important medicines to market for hard t treat diseases. On the other hand, we also have a group that is manufacturing rare cannabinoids for the health and wellness space, so things that will be sold over the counter, such as the CBD mark t, for instance. Those two sides are joined by manufacturing know-how and a general understanding of this class of compounds that we call rare cannabinoids."
@InMedPharma #cannabinoids #rarecannabinoids #rarecannabinoid #cannabinol #CBN #glaucoma #minorcannabinoids #ophthalmology #epidermolysisbullosa #rarediseases #science #pharma
